These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34207124)

  • 1. Molecular and Dynamic Evaluation of Proteins Related to Resistance to Neoadjuvant Treatment with Chemoradiotherapy in Circulating Tumor Cells of Patients with Locally Advanced Rectal Cancer.
    Silva VSE; Abdallah EA; Flores BCT; Braun AC; Costa DJF; Ruano APC; Gasparini VA; Silva MLG; Mendes GG; Claro LCL; Calsavara VF; Aguiar Junior S; de Mello CAL; Chinen LTD
    Cells; 2021 Jun; 10(6):. PubMed ID: 34207124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and Kinetic Analyses of Circulating Tumor Cells as Predictive Markers of Treatment Response in Locally Advanced Rectal Cancer Patients.
    Troncarelli Flores BC; Souza E Silva V; Ali Abdallah E; Mello CAL; Gobo Silva ML; Gomes Mendes G; Camila Braun A; Aguiar Junior S; Thomé Domingos Chinen L
    Cells; 2019 Jun; 8(7):. PubMed ID: 31247977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study.
    Bahnassy AA; Abdel-Azim YA; Ezzat S; Abdellateif MS; Zekri AN; Mohanad M; Salama A; Khaled H
    Mol Biol Rep; 2020 Dec; 47(12):9645-9657. PubMed ID: 33174084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.
    Tan BR; Thomas F; Myerson RJ; Zehnbauer B; Trinkaus K; Malyapa RS; Mutch MG; Abbey EE; Alyasiry A; Fleshman JW; McLeod HL
    J Clin Oncol; 2011 Mar; 29(7):875-83. PubMed ID: 21205745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients.
    Abdallah EA; Fanelli MF; Buim ME; Machado Netto MC; Gasparini Junior JL; Souza E Silva V; Dettino AL; Mingues NB; Romero JV; Ocea LM; Rocha BM; Alves VS; Araújo DV; Chinen LT
    Int J Cancer; 2015 Sep; 137(6):1397-405. PubMed ID: 25721610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer.
    Zhang Y; Yan L; Wu Y; Xu M; Liu X; Guan G
    BMC Cancer; 2020 Sep; 20(1):854. PubMed ID: 32891131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
    Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
    J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis.
    Chang L; Zhang X; He L; Ma Q; Fang T; Jiang C; Ma Z; Li Q; Wu C; Tao J
    Oncologist; 2023 Dec; 28(12):e1198-e1208. PubMed ID: 37294663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery.
    Magni E; Botteri E; Ravenda PS; Cassatella MC; Bertani E; Chiappa A; Luca F; Zorzino L; Bianchi PP; Adamoli L; Sandri MT; Zampino MG
    Int J Colorectal Dis; 2014 Sep; 29(9):1053-9. PubMed ID: 25008360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
    De Palma FDE; Luglio G; Tropeano FP; Pagano G; D'Armiento M; Kroemer G; Maiuri MC; De Palma GD
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.
    Jacobs L; van der Vlies E; Ten Bokkel Huinink D; Bloemendal H; Intven M; Smits AB; Weusten BLAM; Siersema PD; van Lelyveld N; Los M
    Clin Colorectal Cancer; 2018 Sep; 17(3):179-186. PubMed ID: 29661620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients.
    Xu K; Yin X; Zhou B; Zheng X; Wang H; Chen J; Cai X; Gao H; Xu X; Wang L; Shen L; Guo T; Zheng S; Li B; Shao Y; Wang J
    Cancer Lett; 2023 May; 562():216145. PubMed ID: 36997107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastasis risk stratification and response prediction through dynamic viable circulating tumor cell counts for rectal cancer in a neoadjuvant setting.
    Liu WY; Zhang W; Tang Y; Chen SL; Li N; Lei JQ; Shi JM; Wang SL; Li YX; Zhang KT; Jin J
    Cancer Med; 2023 May; 12(10):11438-11450. PubMed ID: 37014817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing a prediction model based on MRI for pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Wan L; Zhang C; Zhao Q; Meng Y; Zou S; Yang Y; Liu Y; Jiang J; Ye F; Ouyang H; Zhao X; Zhang H
    Abdom Radiol (NY); 2019 Sep; 44(9):2978-2987. PubMed ID: 31327039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer.
    Hinz S; Röder C; Tepel J; Hendricks A; Schafmayer C; Becker T; Kalthoff H
    BMC Cancer; 2015 Dec; 15():953. PubMed ID: 26674974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ceRNA Networks: The Backbone Role in Neoadjuvant Chemoradiotherapy Resistance/Sensitivity of Locally Advanced Rectal Cancer.
    He L; Chang H; Qi Y; Zhang B; Shao Q
    Technol Cancer Res Treat; 2021; 20():15330338211062313. PubMed ID: 34908512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Soluble Immune Checkpoints.
    Ari A; Sevik H; Sevinc MM; Tatar C; Buyukasik K; Surel AA; Idiz UO
    Cancer Biother Radiopharm; 2024 Apr; 39(3):247-254. PubMed ID: 38010745
    [No Abstract]   [Full Text] [Related]  

  • 19. The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Meng X; Huang Z; Wang R; Jiao Y; Li H; Xu X; Feng R; Zhu K; Jiang S; Yan H; Yu J
    Radiat Oncol; 2014 Aug; 9():188. PubMed ID: 25159232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
    Sun Y; Wu X; Zhang Y; Lin H; Lu X; Huang Y; Chi P
    Eur J Surg Oncol; 2019 Jul; 45(7):1225-1231. PubMed ID: 30879932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.